Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SURVIVE HERoes - A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

NCT06643585 is registered in ClinicalTrials.gov with Prof. Wolfgang Janni as lead sponsor.

NCT NCT06643585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06643585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SURVIVE HERoes - A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Lead sponsor
Prof. Wolfgang Janni
Phase
Phase 3
Overall status
Recruiting
Start date
April 22, 2025
Completion date
April 22, 2032
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer